RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI)

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $3.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI)

The analyst comments "Reflecting on ASCO and digesting the latest selinexor updates, we believe the longer follow-up data in TP53wt EC, KOL perspectives on the unmet need patient segments in EC despite IO availability, and the latest medical community views around MF drug development all support selinexor's potential in its label expansion opportunities. Though we acknowledge seli is in or entering crowded oncology spaces and has finite small molecule exclusivity, with investor views likely still skewed by historical tolerability issues from early MM studies, $400-500M out-year U.S. sales potential upon successes, and the recent debt restructuring extending the capital runway, we see a favorable reward/risk setup into 2025 readouts."

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $0.96 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Bending Spoons (BSP) PT Raised to $50 at Benchmark on Inaugural Earnings, Revenue Beat
• Oculis Holding AG (OCS) Reiterated at Buy by Stifel After CEO Chat